Burning Rock Biotech (BNR) Invested Capital (2019 - 2026)

Burning Rock Biotech (BNR) has reported Invested Capital for 8 consecutive years, with $74.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital fell 5.17% year-over-year to $74.6 million; the TTM figure through Mar 2026 stood at $74.6 million (down 5.17% YoY), while the FY2025 annual figure was $76.6 million, down 3.77% from the prior year.
• Invested Capital came in at $74.6 million for Q1 2026 at Burning Rock Biotech, down from $75.5 million in the prior quarter.
• The five-year high for Invested Capital was $260.7 million in Q1 2022, with the low at $74.6 million in Q1 2026.
• Average Invested Capital over 5 years is $122.6 million, with a median of $99.3 million recorded in 2024.
• Across the five-year window, Invested Capital slumped 43.64% in 2022 and declined 5.17% in 2026, its largest moves.
• Year by year, Invested Capital stood at $162.9 million in 2022, then plunged by 34.47% to $106.7 million in 2023, then slipped by 24.23% to $80.9 million in 2024, then decreased by 6.63% to $75.5 million in 2025, then retreated by 1.2% to $74.6 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $74.6 million, $75.5 million, and $76.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.